Gilead grants licenses for generic HIV drug production

Original Article by Reuters | 3 October 2024

Gilead Sciences has granted royalty-free licenses to six generic drug manufacturers for the HIV prevention drug lenacapavir in 120 low-income countries.

Gilead Sciences has granted royalty-free licenses to six generic drug manufacturers for the HIV prevention drug lenacapavir in 120 low-income countries.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here